Guillain-Barré syndrome

Expert Review of Neurotherapeutics

Volumn 15, Issue 8, 2015, Pages 847-849

  Wakerley, Benjamin R ^a   Yuki, Nobuhiro ^b  

^a GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

anti ganglioside antibodies; complement cascade; GuillainBarresyndrome; miller fisher syndrome; molecular mimicry

Indexed keywords

BACTERIAL VIRULENCE; CELLULAR IMMUNITY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CYTOMEGALOVIRUS; DISEASE COURSE; EARLY DIAGNOSIS; ELECTRODIAGNOSIS; EPSTEIN BARR VIRUS; EXTRAOCULAR MUSCLE; GUILLAIN BARRE SYNDROME; HUMAN; IN VITRO STUDY; MYCOPLASMA PNEUMONIAE; NERVE CONDUCTION; NEUROPATHY; NONHUMAN; OPHTHALMOPLEGIA; QUADRIPLEGIA; REVIEW; STREPTOCOCCUS PYOGENES; GUILLAIN-BARRE SYNDROME;

GUILLAIN-BARRE SYNDROME; HUMANS;

EID: 84937828409     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2015.1065732     Document Type: Review

References (22)

1. Yuki N, Hartung HP. Guillain-Barre syndrome. N Engl J Med 2012;366(24): 2294-304
2. Wakerley BR, Uncini A, Yuki N. GBS Classification group. Guillain-Barre and Miller Fisher syndromes: new diagnostic classification. Nat Rev Neurol 2014;10(9): 537-44
3. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956;255(2):57-65
4. Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis: its role in pathogenesis. Medicine (Baltimore) 1969;48(3):173-215
5. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993;33(4):333-42
6. Uncini A, Manzoli C, Notturno F, Capasso M. Pitfalls in electrodiagnosis of Guillain-Barre syndrome subtypes. J Neurol Neurosurg Psychiatry 2010;81(10):1157-63
7. Wakerley BR, Yuki N. Infectious and noninfectious triggers in Guillain-Barre syndrome. Expert Rev Clin Immunol 2013; 9(7):627-39
8. Susuki K, Rasband MN, Tohyama K, et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007;27(15):3956-67
9. Yuki N, Taki T, Inagaki F, et al. A bacterium lipopolysaccharide that elicits Guillain-Barre syndrome has a GM1 ganglioside-like structure. J Exp Med 1993;178(5): 1771-5
10. Yuki N, Susuki K, Koga M, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci USA 2004; 101(31):11404-9
11. Koga M, Gilbert M, Li J, et al. Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry. Neurology 2005;64(9):1605-11
12. Chiba A, Kusunoki S, Obata H, et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in miller fisher syndrome and Guillain-Barre syndrome: clinical and immunohistochemical studies. Neurology 1993;43(10): 1911-17
13. Hughes RAC, van Doorn PA. Corticosteroids for Guillain-Barre syndrome. Cochrane Database Syst Rev 2012;8: CD001446
14. Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 2014;9:CD002063
15. Raphael JC, Chevret S, Hughes RAC, Annane D. Plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst. Rev 2012;7:CD001798
16. Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004;350(6):552-9
17. Nürnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009;360(23): 542-4
18. Howard JF Jr, Barohn RJ, Cutter GR, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve 2013;48(1):76-84
19. Halstead SK, Zitman FM, Humphreys PD, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008;131(5):1197-208
20. Fitzpatrick AM, Mann CA, Barry S, et al. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst 2011;16(2):84-91
21. Phongsisay V, Susuki K, Matsuno K, et al. Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barre syndrome. J Neuroimmunol 2008;205(1-2): 101-4
22. Takahashi R, Yuki N. Streptococcal IdeS: therapeutic potential for Guillain-Barre syndrome. Sci Rep 2015; In press